Optimal epitope composition after antigen screening using a live bacterial delivery vector

References

• Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 2004; 113:1515 - 1525
   PubMed Web of Science ®Google Scholar
• Coley W. The treatment of malignant tumors by repeated inoculation of erysipelas. Report of ten original cases. Am J Med Sci 1893;
   Google Scholar
• Alexandroff AB, Jackson AM,, O'Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999; 353:1689 - 1694
   PubMed Web of Science ®Google Scholar
• Sznol M, Lin SL, Bermudes D, Zheng LM, King I. Use of preferentially replicating bacteria for the treatment of cancer. J Clin Invest 2000; 105:1027 - 1030
   PubMed Web of Science ®Google Scholar
• Frankel AE, Fleming DR, Powell BL, Gartenhaus R. DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia. Expert Opin Biol Ther 2003; 3:179 - 186
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000; 18:1622 - 1636
   PubMed Web of Science ®Google Scholar
• Mueller CA, Broz P, Cornelis GR. The type III secretion system tip complex and translocon. Mol Microbiol 2008; 68:1085 - 1095
   PubMed Web of Science ®Google Scholar
• Epaulard O, Toussaint B, Quenee L, Derouazi M, Bosco N, Villiers C, et al. Anti-tumor immunotherapy via antigen delivery from a live attenuated genetically engineered Pseudomonas aeruginosa type III secretion system-based vector. Mol Ther 2006; 14:656 - 661
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Sato E, Briones G, Chen LM, Matsuo M, Nagata Y,, et al. In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J Clin Invest 2006; 1
   Google Scholar
• Polack B, Vergnaud S, Paclet MH, Lamotte D, Toussaint B, Morel F. Protein delivery by Pseudomonas type III secretion system: Ex vivo complementation of p67(phox)-deficient chronic granulomatous disease. Biochem Biophys Res Commun 2000; 275:854 - 858
   PubMed Web of Science ®Google Scholar
• Derouazi M, Toussaint B, Quenee L, Epaulard O, Guillaume M, Marlu R, et al. High-yield production of secreted active proteins by the Pseudomonas aeruginosa type III secretion system. Appl Environ Microbiol 2008; 74:3601 - 3604
   PubMed Web of Science ®Google Scholar
• Pasqual N, Gallagher M, Aude-Garcia C, Loiodice M, Thuderoz F, Demongeot J, et al. Quantitative and qualitative changes in V-J alpha rearrangements during mouse thymocytes differentiation: implication for a limited T cell receptor alpha chain repertoire. J Exp Med 2002; 196::163 - 173
   PubMed Web of Science ®Google Scholar
• Hueck CJ. Type III protein secretion systems in bacterial pathogens of animals and plants. Microbiol Mol Biol Rev 1998; 62::379 - 433
   PubMed Web of Science ®Google Scholar
• Filopon D, Merieau A, Bernot G, Comet JP, Leberre R, Guery B, et al. Epigenetic acquisition of inducibility of type III cytotoxicity in P. aeruginosa. BMC Bioinformatics 2006; 7:272
   PubMed Web of Science ®Google Scholar
• Moore JT, Davis ST, Dev IK. The development of beta-lactamase as a highly versatile genetic reporter for eukaryotic cells. Anal Biochem 1997; 247:203 - 209
   PubMed Web of Science ®Google Scholar
• Zlokarnik G, Negulescu PA, Knapp TE, Mere L, Burres N, Feng L, et al. Quantitation of transcription and clonal selection of single living cells with beta-lactamase as reporter. Science 1998; 279:84 - 88
   PubMed Web of Science ®Google Scholar
• Bloom MB, Perry-Lalley D, Robbins PF, Li Y, el-Gamil M, Rosenberg SA, et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997; 185:453 - 459
   PubMed Web of Science ®Google Scholar
• Leslie MC, Zhao YJ, Lachman LB, Hwu P, Wu GJ, Bar-Eli M. Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis. Gene Ther 2007; 14:316 - 323
   PubMed Web of Science ®Google Scholar
• Andersen MH, Pedersen LO, Becker JC, Straten PT. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res 2001; 61:869 - 872
   PubMed Web of Science ®Google Scholar
• Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of “self”-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998; 188:277 - 286
   PubMed Web of Science ®Google Scholar
• Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50:213 - 219
   PubMed Web of Science ®Google Scholar
• Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994; 152:163 - 175
   PubMed Web of Science ®Google Scholar
• Singh H, Raghava GP. ProPred1: prediction of promiscuous MHC Class-I binding sites. Bioinformatics 2003; 19:1009 1014
   PubMed Web of Science ®Google Scholar
• Reche PA, Glutting JP, Zhang H, Reinherz EL. Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles. Immunogenetics 2004; 56:405 - 419
   PubMed Web of Science ®Google Scholar
• Yahr TL, Mende-Mueller LM, Friese MB, Frank DW. Identification of type III secreted products of the Pseudomonas aeruginosa exoenzyme S regulon. J Bacteriol 1997; 179:7165 - 7168
   PubMed Web of Science ®Google Scholar
• Rocha B, Tanchot C. Towards a cellular definition of CD8+ T-cell memory: the role of CD4+ T-cell help in CD8+ T-cell responses. Curr Opin Immunol 2004; 16:259 - 263
   PubMed Web of Science ®Google Scholar
• Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994; 1:751 - 761
   PubMed Web of Science ®Google Scholar
• Nijman HW, Van der Burg SH, Vierboom MP, Houbiers JG, Kast WM, Melief CJ. p53, a potential target for tumor-directed T cells. Immunol Lett 1994; 40:171 - 178
   PubMed Web of Science ®Google Scholar
• Pelte C, Cherepnev G, Wang Y, Schoenemann C, Volk HD, Kern F. Random screening of proteins for HLAA* 0201-binding nine-amino acid peptides is not sufficient for identifying CD8 T cell epitopes recognized in the context of HLA-A*0201. J Immunol 2004; 172:6783 - 6789
   PubMed Web of Science ®Google Scholar
• Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369–377 from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res 1998; 58:4902 - 4908
   PubMed Web of Science ®Google Scholar
• Kubori T, Matsushima Y, Nakamura D, Uralil J, Lara-Tejero M, Sukhan A, et al. Supramolecular structure of the Salmonella typhimurium type III protein secretion system. Science 1998; 280:602 - 605
   PubMed Web of Science ®Google Scholar
• Lloyd SA, Norman M, Rosqvist R, Wolf-Watz H. Yersinia YopE is targeted for type III secretion by N-terminal, not mRNA, signals. Mol Microbiol 2001; 39:520 - 531
   PubMed Web of Science ®Google Scholar
• Shen DK, Quenee L, Bonnet M, Kuhn L, Derouazi M, Lamotte D, et al. Orf1/SpcS chaperones ExoS for type three secretion by Pseudomonas aeruginosa. Biomed Environ Sci 2008; 21:103 - 109
   PubMed Web of Science ®Google Scholar
• Woestyn S, Sory MP, Boland A, Lequenne O, Cornelis GR. The cytosolic SycE and SycH chaperones of Yersinia protect the region of YopE and YopH involved in translocation across eukaryotic cell membranes. Mol Microbiol 1996; 20:1261 - 1271
   PubMed Web of Science ®Google Scholar
• Prins RM, Odesa SK, Liau LM. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res 2003; 63:8487 - 8491
   PubMed Web of Science ®Google Scholar
• Seifert U, Liermann H, Racanelli V, Halenius A, Wiese M, Wedemeyer H, et al. Hepatitis C virus mutation affects proteasomal epitope processing. J Clin Invest 2004; 114:250 - 259
   PubMed Web of Science ®Google Scholar
• Textoris-Taube K, Henklein P, Pollmann S, Bergann T, Weisshoff H, Seifert U, et al. The N-terminal flanking region of the TRP2360–368 melanoma antigen determines proteasome activator PA28 requirement for epitope liberation. J Biol Chem 2007; 282:12749 - 12754
   PubMed Web of Science ®Google Scholar
• Robbins PF, El-Gamil M, Li YF, Zeng G, Dudley M, Rosenberg SA. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma. J Immunol 2002; 169:6036 - 6047
   PubMed Web of Science ®Google Scholar
• Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996; 184:2207 - 2216
   PubMed Web of Science ®Google Scholar
• Noppen C, Levy F, Burri L, Zajac P, Remmel E, Schaefer C, et al. Naturally processed and concealed HLA-A2.1-restricted epitopes from tumor-associated antigen tyrosinase-related protein-2. Int J Cancer 2000; 87:241 - 246
   PubMed Web of Science ®Google Scholar
• Lehmann JM, Holzmann B, Breitbart EW, Schmiegelow P, Riethmuller G, Johnson JP. Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000. Cancer Res 1987; 47:841 - 845
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr, Colella TA, Thompson L, Graham DD, Skipper JC, Caldwell J, et al. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunol Immunother 2000; 48:661 - 672
   PubMed Web of Science ®Google Scholar